Allogene Therapeutics is launching what it calls the first pivotal Phase II trial of an allogeneic CAR T product in the industry. The ALPHA2 trial will evaluate ALLO-501A in relapsed/refractory large B-cell lymphoma (LBCL). In addition to the ALPHA2 trial, the company is working to initiate the EXPAND trial to evaluate the effects of ALLO-647 when added to the standard fludarabine/cyclophosphamide lymphodepletion treatment regimen.
Allogene is attempting to develop an allogeneic CAR T therapy, sometimes referred to as off-the-shelf. One of the downsides of autologous cell therapies is they are labor-intensive, time-consuming, and expensive. In contrast, an allogeneic CAR T product draws on a variety of healthy donors’ T-cells, which are then engineered to express CARs, then further engineered to decrease the risk of graft-vs-host disease (GVHD) and allogeneic rejection. The product can be stored off the shelf for use as needed.
Read more here
Don’t miss the next article from HealthFirst 100.
Join our mailing list to receive the latest posts from our blog directly in your inbox.